Erythromycin
( DrugBank: Erythromycin / KEGG DRUG: Erythromycin, Erythromycin estolate, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate, Erythromycin gluceptate, Erythromycin thiocyanate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
| 164 | Oculocutaneous albinism | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 228 | Bronchiolitis obliterans | 1 |
| 291 | Hirschsprung disease, entire colon type | 1 |
6. Parkinson disease
Clinical trials : 2,586 / Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
164. Oculocutaneous albinism
Clinical trials : 16 / Drugs : 44 - (DrugBank : 27) / Drug target genes : 30 - Drug target pathways : 137
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
228. Bronchiolitis obliterans
Clinical trials : 108 / Drugs : 95 - (DrugBank : 30) / Drug target genes : 34 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
291. Hirschsprung disease, entire colon type
Clinical trials : 14 / Drugs : 26 - (DrugBank : 9) / Drug target gene : 0 - Drug target pathway : 0
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|